JCAD

Across TCGA pan-cancer cohorts, JCAD mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated JCAD data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher JCAD mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated JCAD expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

GBM, PDAC, and COAD are the cancer types where JCAD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.891	0.680	<.001	28	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	15	view →
COAD	DFS	Median	III,IV	0.838	1.000	.045	12	view →
LUAD	DFS	Tertile	II,III,IV	0.709	0.962	.028	9	view →
LSCC	DFS	Tertile	II,III,IV	0.874	1.000	.036	3	view →
HNSC	OS	Quartile	III,IV	0.965	0.817	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

JCAD–GBM (DFS)

Open the GBM breakdown →